Condition: Glaucoma, Neovascular · Vascular Endothelial Growth Factor Overexpression · Sponsor: Prince of Songkla University
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.
This description comes directly from the study's public registry record.
Assoc.Prof.Weerawat Kiddee, MD · +66874954626 · kweerawat@hotmail.com
Always discuss trial participation with your own doctor first.
| Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University | Hat Yai, Changwat Songkhla, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03648814